/JAZZ
Jazz Pharmaceuticals plc
JAZZ • NASDAQJAZZ • NASDAQ • Healthcare
$180.13-0.11%-0.19
$180.13-0.11%(-0.19)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
100Bullish
Risk
100Low Risk
Momentum
88Positive
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
88.2%▼0.8pp
Revenue after COGS
Operating
5.3%▼12.4pp
After operating expenses
Net
-8.3%▼22.1pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
-29.1
Price vs earnings
EV/EBITDA
132.8
Enterprise value
FCF Yield
12.5%
Cash generation
Earnings Yield
-3.4%
Inverse of P/E
Capital Efficiency
-2
GoAI Quality ScorePoor
ROEReturn on Equity
-8.2%Weak
ROAReturn on Assets
-3.1%Weak
ROICReturn on Invested Capital
1.2%Fair
Financial Health
Current RatioHealthy
1.86
Short-term solvency (>1.5)
Net Debt / EBITDAHigh
37.17x
Debt repayment capacity (<3x)
Income QualityWeak
-3.81
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B |
| Gross Profit | $3.76B | $3.62B | $3.40B | $3.12B | $2.65B |
| Gross Margin | 88.2% | 89.0% | 88.6% | 85.2% | 85.8% |
| Operating Income | $224.42M | $716.63M | $578.58M | -$65.53M | $170.28M |
| Net Income | -$356.15M | $560.12M | $414.83M | -$224.06M | -$328.95M |
| Net Margin | -8.3% | 13.8% | 10.8% | -6.1% | -10.6% |
| EPS | -$5.84 | $9.06 | $6.55 | -$3.58 | -$5.51 |
Average Price Target
$207.86▲ 15.4% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Jazz Pharmaceuticals plc, the average price target is $207.86, with a high forecast of $235.00 and a low forecast of $170.00. The average price target represents a 15.4% increase from the current price of $180.13.
Highest
$235.00
Average
$207.86
Lowest
$170.00
Rating Distribution
Strong Buy
0
0%
Buy
41
87%
Hold
6
13%
Sell
0
0%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
RBC Capital● Maintain
Outperform
2026-02-25B of A Securities● Maintain
Buy
2026-02-25Wells Fargo● Maintain
Overweight
2026-02-25Morgan Stanley● Maintain
Overweight
2026-02-25Needham● Maintain
Buy
2026-01-12Truist Securities● Maintain
Buy
2026-01-12Piper Sandler● Maintain
Overweight
2025-12-10UBS▼ Downgrade
Buy→Neutral
2025-11-24Wells Fargo● Maintain
Overweight
2025-11-18B of A Securities● Maintain
Buy
2025-11-18Earnings History & Surprises
BEAT RATE
56%
Last 18 quarters
AVG SURPRISE
-6.6%
EPS vs Estimate
BEATS / MISSES
10/8
Last 18 quarters
LATEST EPS
$6.64
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+1.8%
$6.64 vs $6.52
Q4 '25
+36.6%
$8.13 vs $5.95
Q3 '25
-34.8%
$-8.25 vs $-6.12
Q2 '25
-62.7%
$1.68 vs $4.51
Q1 '25
+13.2%
$6.60 vs $5.83
Q4 '24
+20.8%
$6.61 vs $5.47
Q3 '24
+13.2%
$5.30 vs $4.68
Q2 '24
-35.3%
$2.68 vs $4.14
Q1 '24
-4.6%
$5.02 vs $5.26
Q4 '23
-1.2%
$4.84 vs $4.90
Q3 '23
+1.1%
$4.51 vs $4.46
Q2 '23
-7.3%
$3.95 vs $4.26
No investor questions available.
Latest News
No news available